Mozafancogene autotemcel - Rocket Pharmaceuticals
Alternative Names: LV-RP-L102; RP L102; RP-L02Latest Information Update: 19 May 2025
At a glance
- Originator CIEMAT
- Developer CIEMAT; Rocket Pharmaceuticals
- Class Antianaemics; Gene therapies; Stem cell therapies
- Mechanism of Action Fanconi anaemia complementation group protein replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Fanconi's anaemia
Most Recent Events
- 08 May 2025 Rocket Pharmaceuticals expects to submit the final module of its filing in late 2025 or early 2026
- 07 Nov 2024 Preregistration for Fanconi's anaemia (In adolescents, In children, In the elderly, In infants, In adults) in USA (IV)
- 30 Apr 2024 European Medicines Agency accepts the Marketing Authorization Application (MAA) for Mozafancogene autotemcel for Fanconi's anaemia